Food allergy aff ects roughly 15 million Americans and 17 million Europeans, most being young children. 1, 2 At present, there is no known treatment or cure. However, oral immunotherapy (OIT) is a promising investigational therapy which aims to produce allergen desensitisation through graduated dose exposure to an allergen (eg, temporary tolerance from continuing controlled exposure to an allergen, which wanes if ongoing exposure is withdrawn). Over time, a lasting tolerance to incidental allergen ingestion might remove the need for continued ongoing exposure.
In The Lancet, Katherine Anagnostou and colleagues report the results of the STOP II trial, 4 a two-step, phase 2, unmasked, randomised controlled crossover trial of peanut OIT in 99 children aged 7-16 years, inclusive of all severities of peanut allergy. In the fi rst phase, participants were randomly assigned to receive either 26 weeks of OIT to 800 mg of peanut protein, or peanut avoidance (the standard of care). Both groups then underwent a double-blind, placebo-controlled, peanut challenge, and in a second phase the control group was off ered the 26 week OIT protocol and challenge. Among OIT participants, 91% (95% CI 79-98) were desensitised to 800 mg, the equivalent of fi ve peanuts. In terms of the trial's primary outcome, 24 of 39 OIT participants were desensitised to 1400 mg of peanut protein (the
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ISN also supports about 50 continuing medical education programmes a year in LMICs, providing international experts who supplement local speakers and also meet with local health-care leaders-sometimes health ministers-to assess needs and opportunities for nephrology and work out how ISN can contribute.
The global outreach programmes are continuously assessed and improved using survey data and local feedback. They are oversubscribed, and selection for funding is based on objective criteria for the relevance of the proposal to the needs of the individual, the centre, and the country. In 2012, worldwide, ISN supported 48 fellows, 37 sister centres, 48 continuing medical education programmes, 16 educational ambassadors, and six research and prevention grants at an aggregate cost of just US$1·5 million, representing, in line with its mission, every spare dollar in the ISN budget (after running costs of the society were covered). The low costs are a result of reduced costs of staff and services in LMICs: ISN members gladly volunteer their time as teachers and trainers, travel in economy class, and stay in low-cost local accommodation, and sister centres and centres hosting fellows make creative use of their own budgets to benefi t their partners. The distribution of these ISN programmes funded in 2012 in Africa is shown in the fi gure.
ISN will continue to develop these programmes as its top priority and will partner with any organisation with the same respect for the achievements in nephrology care of our colleagues in developing countries, and with the same commitment to supporting sustainable, transformational capacity building as the ISN. The results that the ISN aim for happen when committed LMIC leaders work with ISN leaders and volunteers, and when everyone involved understands that, although progress might be slow, patience and perseverance are rewarded.
The ISN's model and achievements provide a meaningful answer to how medical care in developing countries might be improved. We recommend our model to other professional medical societies and to individuals who want to help make a real and lasting diff erence in health care in developing regions of the world. Previous studies have concluded that OIT can safely produce desensitisation to peanut and other allergens among selected, but not all, participants. These studies have signifi cant methodological concerns, including small sample sizes, selection bias (involving referral centre populations of older children without past severe reactions and with motivated caregivers), and lack of control groups or pre-OIT challenge to confi rm that the patient still has persistent allergy. [5] [6] [7] [8] [9] [10] In particular, caregiver participation bias might substantially aff ect study results, although this is probably an unavoidable constraint dictated by limited selection pools. In past peanut OIT studies, high proportions of participants developed adverse reactions, including anaphylaxis; dropout was high; and no mechanism of action for the immunological eff ects was clearly identifi ed. Moreover, because adverse events have been reported at the dose level (the convention for inhalant/venom immunotherapy) and not the patient level, the high total proportion of all participants experiencing adverse reactions has been obscured when spread across several thousand total doses. Notably, patients deliberately screened to be less reactive by history have experienced more severe reactions than baseline during OIT, and not all participants achieve desensitisation. 6, 7, 9, 11 Poor data exist to predict successes from failures. Therefore, previous conclusions that OIT is safe and eff ective might be somewhat subjective.
*
Anagnostou and colleagues have avoided most of these methodological concerns. They report fewer side-eff ects with little epinephrine use among OIT participants, enrolled community participants and individuals with previous severe peanut reactions, required entry food challenges, and focused on quality of life as a key outcome. 4 These are substantial changes from earlier peanut OIT studies, but a few problems with the methods remain, such as lack of masking, participation bias (use of a community sample recruited through a food allergy advocacy group), a roughly 10% dropout, unclear power for the analysis of the quality of life outcome, and use of a truncated peak dose (1400 mg) with uncertain clinical importance compared with other trials that far exceeded this peak dose. 4, 5, [8] [9] [10] 12 Therefore, the validity and generalisability of past and ongoing OIT studies should be questioned, as with any early phase research. Although these concerns should not diminish the value of the results so far, which are exceptionally promising, OIT remains experimental. 13 OIT is not ready for clinical use until the short-term eff ects have been comprehensively proven, and the long-term side-eff ects, mechanism of action, and outcomes are known. Furthermore, a common protocol and delivery vehicle should be decided upon, since this has varied across studies. 4, 6, [8] [9] [10] 12 It is unknown if OIT can produce lasting tolerance, a key outcome. Although one peanut study and one egg study have shown that certain participants can withstand a 2 week (peanut) or 4-6 week (egg) interruption of OIT and remain tolerant, these advances are balanced by reports from other OIT studies (milk) of participants developing eosinophilic oesophagitis or redeveloping the allergy after months to years of tolerating therapy. 9, 11, 14, 15 Both are unwanted outcomes, and highlight issues still to be clarifi ed.
Continued OIT studies are needed, but with larger samples that include severely reactive individuals, very young patients, and individuals from both the community and referral centre settings to encompass a robust food-allergic population. Future studies must establish if OIT is cost-eff ective, as well as continue to explore how OIT aff ects quality of life. Importantly, caregiver goals (eg, achieving a cure vs increasing the reaction threshold) need to be understood, which might need diff erent protocols to be developed if many goals exist. Understanding the range and degree of eff ect is also paramount. There is poor understanding of the degree of heterogeneity in disease phenotype that exists across the food-allergic population. However, if there is also heterogeneity of treatment eff ect for OIT then this must be comprehensively shown so the correct populations of food-allergic individuals receive the therapy. It would be naive to view OIT as a one size fi ts all treatment for food allergy but, on the contrary, it would be short-sighted to deem OIT a failure if only a small subset of food-allergic individuals benefi t. www.thelancet.com Vol 383 April 12, 2014
International comparisons of acute myocardial infarction
Sheng-Chia Chung and colleagues 1 report in The Lancet that, in their comparison of short-term outcomes in patients with acute myocardial infarction, unadjusted 30-day mortality was more than a third higher in the UK than in Sweden during 2004-10. They suggest that this diff erence is due largely to the divergent speed of implementation of policy initiatives to improve care. Chung and colleagues compared the UK data with those for Sweden because the two countries have similar health systems for, and spending on, acute myocardial infarction, but diff usion of evidence-based changes to practice and new technologies has been notably quicker in Sweden.
Records for 119 786 patients in Sweden and 391 077 in the UK were assessed. This fundamental prognosis research, 2 which used whole-country data, showed much higher unadjusted mortality in patients with acute myocardial infarction in the UK than in Sweden: 30-day mortality was 10·5% (95% CI 10·4-10·6) in the UK and 7·6% (7·4-7·7) in Sweden. The UK to Sweden standardised mortality ratio was 1·37 (1·30-1·45), which suggests that more than 11 000 deaths due to acute myocardial infarction might have been avoided during the period of the study. Importantly, although the diff erence in mortality rates decreased over time, mortality was always higher in the UK, even in clinical subgroups such as those defi ned by troponin concentration or ST-segment elevation. After standardisation for the Swedish casemix by use of a 17-variable model that took into account patients' risk at baseline, UK 30-day mortality decreased by around 3%. This fi nding suggests that factors from the point of fi rst medical contact to 30 days from hospital admission diff erentially aff ect outcomes.
Chung and colleagues explored what factors might account for the international diff erences in mortality. Their fi ndings imply that between-country diff erences in the use and dissemination of treatments recommended in guidelines was an important factor, as they noted that in the UK the uptake of primary percutaneous coronary
In conclusion, although Anagnostou and colleagues provide further evidence that OIT is a potential treatment for food allergy, 4 more high-quality data are needed. It is important to understand that OIT research cannot be rushed, and is years away from routine clinical use. Investigative groups need time to refi ne protocols, revalidate data, understand the mechanisms of OIT, and minimise adverse eff ects. This must be done without added pressure or heightened expectations to quickly produce a marketable therapy.
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